Every round on record, with the sources behind each and the investors on them.
No description yet.
leadsynbio.comSuzhouFounded 2015
3 sources · checked 1 time, last 39m ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
No source names lead or participating investors, or states a valuation or cumulative financing total.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Growth Pre-IPO round | $67.2M RMB 450 million | ~ 2026-09-28 | not stated | No recent discussion |
3 sources · checked 1 time, last 39m ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 3 sources
No source names lead or participating investors, or states a valuation or cumulative financing total. | ||||
Leadsynbio uses synthetic biology to manufacture pharmaceutical APIs and intermediates plus human- and animal-nutrition ingredients for global customers.
Checked against 10 sources today
None named.
Also named as backers in company research: GL Ventures, Sherpa Healthcare Partners, Lilly Asia Ventures, GF Qianhe Investment, Caixin Industry Fund, Hillhouse Ventures, Asia Green Fund, Caixin Capital, CICC Capital, Jiashan Industrial, Oriza Holdings